Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc

Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database

(2021) Margaret Gartland et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

(2020) Michael Kozal et al.   NEW ENGLAND JOURNAL OF MEDICINE

CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent

(2020) Jingzhe Wang et al.   PHARMACOLOGICAL RESEARCH

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay

(2020) Margaret Gartland et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ibalizumab: A novel monoclonal antibody for the management of multidrug resistant HIV-1 infection

(2019) Mario V. Beccari et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir

(2018) Max Lataillade et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529

(2017) Marie Pancera et al.   Nature Chemical Biology

Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins

(2016) Alon Herschhorn et al.   mBio

Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action

(2014) David R. Langley et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors

(2013) Zhufang Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068

(2013) Neelanjana Ray et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068

(2013) N. Zhou et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients

(2012) Steven FL van Lelyveld et al.   Expert Review of Anti-Infective Therapy

A Single Residue within the V5 Region of HIV-1 Envelope Facilitates Viral Escape from the Broadly Neutralizing Monoclonal Antibody VRC01

(2012) Dongxing Guo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab

(2011) J. Toma et al.   JOURNAL OF VIROLOGY

Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody

(2010) Michael M. Freeman et al.   STRUCTURE